$abla \mathsf{S}$ terne Kessler **Goldstein Fox**

ATTORNEYS AT LAW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig Robert C. Millonia Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Albert J. Fasulo II* Eldora Ellison Floyd

Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Preggaman Rae Lynn Prengaman Jane Shershenovich* George S. Bardmesser Daniel A. Klein* Rodney G. Maze Jason D. Eisenberg Michael A. Specht Andrea J. Kamage Tracy L. Muller Jon E. Wright*

LuAnne M. Yuricek*

Registered Patent Agents Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Angelique G. Uy Mary B. Tung Katrina Y. Pei Katrina Y. Pei Bryan L. Skelton Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford

Of Counsel
Kenneth C. Bass III Lisa A. Dunner Evan R. Smith

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

March 14, 2003

WRITER'S DIRECT NUMBER: (202) 772-8544 INTERNET ADDRESS: MCIMBALA@SKGF.COM

RECEIVED

Commissioner for Patents Washington, D.C. 20231

MAR 1 7 2003

Art Unit 1652

TECH CENTER 1600/2900

Re:

U.S. Utility Patent Application

Appl. No. 09/974,973; Filed: October 12, 2001

Feedback-Resistant Pyruvate Carboxylate Gene from Corynebacterium For:

Inventor:

Paul D. HANKE

Our Ref:

1533.1230001/MAC/RGM

Sir:

Transmitted herewith for appropriate action are the following documents:

- Reply To Restriction Requirement; and 1.
- 2. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala Attorney for Applicant

mily A. anh

Registration No. 33,851

MAC/RGM:krm Enclosures SKGF_DC1:111048.1

Sterne, Kessler, Goldstein & Fox PLL.C.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. 8115

Art Unit: 1652

Examiner: Slobodyansky, E.

Atty. Docket: 1533.1230001/MAC/RGM

In re application of:

Paul D. HANKE

U.S. Appl. No. 09/974,973

Filed: October 12, 2001

For:

Feedback-Resistant Pyruvate Carboxylate Gene from

Corynebacterium

Reply To Restriction Requirement

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Office Action, dated February 14, 2003, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group I, represented by claims 1, 2, 5-8, 12, 13, 19, 20 and 3, drawn to a DNA encoding a polypeptide having the amino acid sequence of SEQ ID NO:2 and fragments thereof, a vector and a host cell comprising thereof and a method of making a host cell, classified in class 435, subclass 463. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed. This election is made with traverse.

The Examiner alleges that Groups I-V are patentably <u>distinct</u> inventions. However, even where patentably distinct inventions appear in a single application, restriction remains improper unless the Examiner can also show that the search and examination of the groups would entail a "serious burden." It is only where the inventions are <u>independent</u>, that the "serious burden" is inherent and need not be explained by the Examiner (*see* MPEP § 803 and 808). In the present application, the Examiner has failed to show that the search and examination of the groups would entail a serious burden. With respect to Groups I, II and IV, V, Applicants submit that a search of either the nucleotide sequence or polypeptide claims

y: ~

Paul D. HANKE Appl. No. 09/974,973

- 2 -

would provide useful information for the remaining claims. Disclosure of the nucleotide inherently describes the predicted polypeptide. Furthermore, many, if not most, publications where a published nucleotide sequence is described, the authors also include, as a matter of routine, the amino acid sequence. Thus, a search for information from restriction groups I and

II will result in a significant amount of information related to restriction groups IV and V, and

vice-versa.

Finally, the Examiner states that Group III is patentably <u>distinct</u> from Groups I, II, IV and V because it is drawn to methods of making of a product that is neither used by nor produced by Groups I, II, IV and V. Applicants respectfully submit that the two prerequisites to proper restriction are that the inventions must be independent or distinct as claimed, <u>and</u> that examination of the inventions would create a "serious burden" (*see* MPEP § 803 and 808). Where the inventions are related but patentably <u>distinct</u>, as the Examiner alleges in the present application, the "serious burden" must be explained by the Examiner; and the Examiner has failed to show that the search and examination of the groups would entail a serious burden.

Applicants submit that the application is fully in condition for examination. An examination on the merits is earnestly solicited.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala Attorney for Applicant

Snichel A. Cimbel

Registration No. 33,851

Date: 3/14/03

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

(202) 371-2600